<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uz">
	<id>https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=D-dimer</id>
	<title>D-dimer - Oʻzgarishlar tarixi</title>
	<link rel="self" type="application/atom+xml" href="https://ziyosfera.uz/index.php?action=history&amp;feed=atom&amp;title=D-dimer"/>
	<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=D-dimer&amp;action=history"/>
	<updated>2026-11-21T22:33:06Z</updated>
	<subtitle>Ziyosferadagi mazkur sahifaning oʻzgarishlar tarixi</subtitle>
	<generator>MediaWiki 1.45.1</generator>
	<entry>
		<id>https://ziyosfera.uz/index.php?title=D-dimer&amp;diff=382154&amp;oldid=prev</id>
		<title>Programmer: Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.</title>
		<link rel="alternate" type="text/html" href="https://ziyosfera.uz/index.php?title=D-dimer&amp;diff=382154&amp;oldid=prev"/>
		<updated>2026-08-10T16:53:26Z</updated>

		<summary type="html">&lt;p&gt;Oʻzbekcha Vikipediyadan (UzWiki) 100% asl holatida import qilindi.&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Yangi sahifa&lt;/b&gt;&lt;/p&gt;&lt;div&gt;&amp;#039;&amp;#039;&amp;#039;D-dimer&amp;#039;&amp;#039;&amp;#039; (yoki &amp;#039;&amp;#039;&amp;#039;D-dimer&amp;#039;&amp;#039;&amp;#039;) — fibrin degradatsiyasi mahsuloti (yoki FDP) boʻlib, qon laxtasi fibrinoliz bilan parchalanganidan keyin qonda mavjud boʻlgan kichik protein boʻlagi hisoblanadi. U shunday nomlanishiga aosiy sabablar bor, chunki u oʻzaro bogʻlanish bilan birlashtirilgan [[fibrin]] oqsilining ikkita „D“ fragmentini oʻz ichiga oladi va shuning uchun oqsil dimerini hosil qiladi&amp;lt;ref&amp;gt;Asakura, Hidesaku; Ogawa, Haruhiko (2020). „COVID-19-associated coagulopathy and disseminated intravascular coagulation“. International Journal of Hematology. 113 (1): 45-57. doi:10.1007/s12185-020-03029-y. ISSN 0925-5710. PMC 7648664. PMID 33161508.&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
D-dimer kontsentratsiyasi [[Tromboz (tibbiyot)|tromboz]] tashxisini qoʻyish uchun qon testi bilan aniqlanishi mumkin&amp;lt;ref name=&amp;quot;khan&amp;quot;&amp;gt;{{jurnal manbasi|last=Khan|first1=Faizan|last2=Tritschler|first2=Tobias|last3=Kahn|first3=Susan R|last4=Rodger|first4=Marc A|title=Venous thromboembolism|journal=The Lancet|year=2021|issn=0140-6736|doi=10.1016/s0140-6736(20)32658-1|pmid=33984268}}&amp;lt;/ref&amp;gt;. 1990-yillarda amaliyotga joriy etilganidan beri u venoz tromboemboliya kabi trombotik kasalliklarga shubha qilingan odamlarda oʻtkaziladigan muhim tekshirish usuliga aylandi&amp;lt;ref name=&amp;quot;khan&amp;quot; /&amp;gt;. Salbiy natija trombozni amalda istisno qiladi, ijobiy natija trombozga oid patologiyani koʻrsatishi mumkin, ammo boshqa mumkin boʻlgan sabablarni istisno qilmaydi&amp;lt;ref name=&amp;quot;ponti&amp;quot; /&amp;gt;. Ushbu tekshiruv amaliyotini oʻtkazilishining asosiy sababi tromboembolitik kasalliklarni istisno qilishdir&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;khan&amp;quot; /&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
D-dimer darajalari qon aylanishi buzilishi, [[DVS sindromi|tarqalgan intravaskulyar koagulyatsiya]] va [[COVID-19 koronavirus infeksiyasi|COVID-19 infektsiyasi]] bilan bogʻliq koagulyatsion buzilishlar uchun eng muhim diagnostik masalani hal qiluvchi biomarker sifatida ishlatiladi&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ponti&amp;quot;&amp;gt;{{jurnal manbasi|last=Ponti|first1=G|last2=Maccaferri|first2=M|last3=Ruini|first3=C|last4=Tomasi|first4=A|last5=Ozben|first5=T|title=Biomarkers associated with COVID-19 disease progression.|journal=Critical Reviews in Clinical Laboratory Sciences|volume=57|issue=6|year=2020|issn=1040-8363|pmid=32503382|pmc=7284147|doi=10.1080/10408363.2020.1770685|pages=389–399}}&amp;lt;/ref&amp;gt;. Proteinning toʻrt baravar koʻpayishi [[COVID-19 koronavirus infeksiyasi|COVID-19]] bilan shifoxonaga yotqizilgan odamlarda yomon patofiziologik jarayon kechayotganligini koʻrsatuvchi asosiy koʻrsatkichidir&amp;lt;ref name=&amp;quot;ponti&amp;quot; /&amp;gt;&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Velavan|first1=Thirumalaisamy P.|last2=Meyer|first2=Christian G.|title=Mild versus severe COVID-19: laboratory markers|journal=International Journal of Infectious Diseases|date=25 April 2020|volume=95|pages=304–307|doi=10.1016/j.ijid.2020.04.061|pmc=7194601|pmid=32344011|url=https://www.ijidonline.com/article/S1201-9712(20)30277-0/fulltext#%20|access-date=25 April 2020}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Prinsiplari ==&lt;br /&gt;
[[Fayl:D-dimer.png|link=//upload.wikimedia.org/wikipedia/commons/c/ce/D-dimer.png|right|frame| &amp;#039;&amp;#039;&amp;#039;D-dimer shakllanishi.&amp;#039;&amp;#039;&amp;#039; Koʻrsatilgan &amp;#039;&amp;#039;[[fibrinogen]]&amp;#039;&amp;#039;, uning bitta &amp;#039;&amp;#039;E&amp;#039;&amp;#039; va ikkita &amp;#039;&amp;#039;D&amp;#039;&amp;#039; domenlari bilan, kaskadda, quyidagi [[fermentlar]] tomonidan taʼsir qiladi: &amp;#039;&amp;#039;Fibrin&amp;#039;&amp;#039; protofibrillalari toʻrini yaratish uchun &amp;#039;&amp;#039;trombin&amp;#039;&amp;#039; ; XIII omil &amp;#039;&amp;#039;fibrin toʻrini oʻzaro&amp;#039;&amp;#039; bogʻlash uchun kerak boʻladi (protofibril D domenlarini bogʻlash), laxta shakllanishi uchun esa ikkala; &amp;#039;&amp;#039;Fibrinolizdagi&amp;#039;&amp;#039; taʼsirida fibrin parchalanish mahsulotlarini (&amp;#039;&amp;#039;FDP&amp;#039;&amp;#039;) ishlab chiqaradigan plazmin, eng kichiki &amp;#039;&amp;#039;D-dimerlar&amp;#039;&amp;#039;, bir E va ikkita oʻzaro bogʻlangan D domeniga ega boʻlgan oqsil parchalari asl fibrinogendan foydalaniladi&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;wells&amp;quot;&amp;gt;{{jurnal manbasi|display-authors=6|title=Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis|journal=The New England Journal of Medicine|volume=349|issue=13|pages=1227–35|date=September 2003|doi=10.1056/NEJMoa023153|pmid=14507948|url=https://www.nejm.org/doi/10.1056/NEJMoa023153}}&amp;lt;/ref&amp;gt;]]&lt;br /&gt;
[[Koagulyatsiya]], qon ivishi yoki trombning shakllanishi, [[Koagulyatsiya|koagulyatsion jarayonning]] oqsillari yoki shikastlangan qon tomir devori bilan aloqa qilish va toʻqima boʻshligʻida (ichki yoʻl) kollagen taʼsirida, shuningdek, asosan eng muhim boʻlgan ikkita sabab bor: VII omilning faollashishi natijasida sodir boʻladigan toʻqimalarni faollashtiruvchi omillar (tashqi yoʻl) tufayli sodir boʻladi. Ikkala yoʻl ham trombin hosil boʻlishiga olib keladi, bu ferment eruvchan qon oqsili [[Fibrin|fibrinogenini]] fibringa aylantiradi va u [[proteofibrillar]]ga aylanadigan, hamda, [[Trombin]] ishlab chiqaradigan yana bir ferment hisoblanadi&amp;lt;ref&amp;gt;Asakura, Hidesaku; Ogawa, Haruhiko (2020). „COVID-19-associated coagulopathy and disseminated intravascular coagulation“. International Journal of Hematology. 113 (1): 45-57. doi:10.1007/s12185-020-03029-y. ISSN 0925-5710. PMC 7648664. PMID 33161508.&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== D-dimer koʻrsatgichi ===&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
|+ Caption text&lt;br /&gt;
|-&lt;br /&gt;
! Yoshi !! D-dimer oʻrtacha koʻrsatgichi !! AQSH Jackson Park Hospital tadqiqoti natijasida D-dimer koʻrsatgichi&lt;br /&gt;
|-&lt;br /&gt;
| 16-39 || 294 || 490&lt;br /&gt;
|-&lt;br /&gt;
| 40-59 || 387 || 400&lt;br /&gt;
|-&lt;br /&gt;
| 60-79 || 854 || 552&lt;br /&gt;
|-&lt;br /&gt;
| 80 + || 1397 || 899&lt;br /&gt;
|}&lt;br /&gt;
&lt;br /&gt;
XIII omil, soʻngra D fragmenti joyida fibrin proteofibrillalarini oʻzaro bogʻlaydi va qon laxtalarini shakllanishi uchun asosiy omil boʻlib xizmat qiladigan erimaydigan gelsimon modda hosil boʻlishiga olib keladi&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
Aylanma ferment plazmini va fibrinolizning asosiy fermenti, fibrin gelini bir qator joylarda parchalaydi. Olingan boʻlaklar, „Yuqori molekulyar ogʻirlikdagi polimerlar“ plazmini tomonidan bir necha marta koʻproq hazm qilinadi va oraliq hamda keyin kichik polimerlar hosil boʻlishiga (fibrin parchalanish mahsulotlari yoki FDP) olib keladi. Natijada ikkita D fragmentlari orasidagi oʻzaro bogʻlanish butun boʻlib qoladi va ular fibrin boʻlaklari yetarlicha hazm boʻlganda sirtda namoyon boʻladi. D-dimerning tuzilishi ikki D domenining 180 [[Massaning atom birligi|kDa]]&amp;lt;ref name=&amp;quot;KoganMukharyamova2016&amp;quot;&amp;gt;{{jurnal manbasi|title=Monoclonal antibodies with equal specificity to D-dimer and high-molecular-weight fibrin degradation products|journal=Blood Coagulation &amp;amp; Fibrinolysis|volume=27|issue=5|pages=542–50|date=July 2016|pmid=26656897|pmc=4935535|doi=10.1097/MBC.0000000000000453}}&amp;lt;/ref&amp;gt; yoki 195 kDa&amp;lt;ref name=&amp;quot;OlsonCunningham2013&amp;quot;&amp;gt;{{jurnal manbasi|title=D-dimer: simple test, tough problems|journal=Archives of Pathology &amp;amp; Laboratory Medicine|volume=137|issue=8|pages=1030–8|date=August 2013|pmid=23899057|doi=10.5858/arpa.2012-0296-CP}}&amp;lt;/ref&amp;gt; ogʻirlikdagi molekulasi, shuningdek ikkita D domenining 340 kDa&amp;lt;ref name=&amp;quot;OlsonCunningham2013&amp;quot; /&amp;gt; molekulasi va asl fibrinogen molekulasining bir E domenidir&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;. Qondagi D-dimerning yarimparchalanish davri taxminan 6 soatdan 8 soatgacha sodir boʻladi&amp;lt;ref name=&amp;quot;pmid20213258&amp;quot;&amp;gt;{{jurnal manbasi|title=Biochemical markers for the diagnosis of venous thromboembolism: the past, present and future|journal=J Thromb Thrombolysis|volume=30|issue=4|pages=459–71|date=November 2010|pmid=20213258|doi=10.1007/s11239-010-0460-x|url=}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
D-dimerlar odatda inson qon plazmasida mavjud boʻlmaydi. Koagulyatsion tizim faollashgan hollarda bundan mustasno boʻlib, [[Tromboz (tibbiyot)|tromboz]] yoki [[DVS sindromi|tarqalgan tomir ichidagi koagulyatsiya]] mavjudligi sababli tahlil oʻtkazilganda natija ijobiy koʻrsatgichni beradi. D-dimer tahlili monoklonal antitelaning D-dimer fragmentidagi maʼlum bir epitopga bogʻlanishiga bogʻliq. Tahlilda bir nechta aniqlash usullari mavjud; ularning barchasi D-dimerga qarshi boshqa monoklonal antitelaga tayanadi. Ulardan baʼzilari uchun antitela bogʻlaydigan D-dimerning maydoni maʼlum. Keyin antitelaning bogʻlanishi turli xil laboratoriya usullaridan biri bilan miqdoriy jihatdan oʻlchanadi&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== D-dimer ortish sabablari ==&lt;br /&gt;
Dastlab D-dimerning yuqori konsentratsiyasi boʻlgan bemorlarda past konsentratsiyali bemorlarga qaraganda venoz tromboembolik asoratlarni (VTEA) rivojlanish xavfi taxminan 3,5 baravar yuqori hisoblanadi.&lt;br /&gt;
&amp;#039;&amp;#039;VTEA quyidagilarni oʻz ichiga oladi:&amp;#039;&amp;#039;&lt;br /&gt;
* pastki ekstremitalarning chuqur tomir trombozi;&lt;br /&gt;
* teri osti venalarining trombozi;&lt;br /&gt;
* oʻpka emboliyasi (OʻE).&lt;br /&gt;
[[Fayl:Alcoholic hepatitis.jpg|thumb|300px|right|D-dimer koʻrsatgichi oshgan toʻqimaning patologik koʻrinishi (Gepatit)]]&lt;br /&gt;
&lt;br /&gt;
VTEA rivojlanishida quyidagilar xavf ostida boʻladi:&lt;br /&gt;
* keksa odamlar;&lt;br /&gt;
* ortiqcha vaznli odamlar;&lt;br /&gt;
* homilador ayollar;&lt;br /&gt;
* yurak-qon tomir kasalliklari (CVD) bilan ogʻrigan bemorlar;&lt;br /&gt;
* intensiv terapiya boʻlimida (ICU) insultdan keyin bemorlar;&lt;br /&gt;
* keng qamrovli jarrohlik aralashuvlar, jarohatlar, kuyishlar bilan ogʻrigan bemorlar;&lt;br /&gt;
* saraton kasalligi bilan ogʻrigan bemorlar;&lt;br /&gt;
* septik bemorlar.&lt;br /&gt;
&lt;br /&gt;
D-dimer venoz tromboembolik asoratlar boʻlmasa ham ortishi mumkin. Buning sabablari quyidagilar boʻlishi mumkin:&lt;br /&gt;
* Davolashdan oldingi 7 kun ichida fibrinolitik terapiya (qon preparatlarini quyishga qaratilgan terapiya);&lt;br /&gt;
* [[miokard infarkti]];&lt;br /&gt;
* ateroskleroz;&lt;br /&gt;
* [[sepsis]],&lt;br /&gt;
* ogʻir infeksiyalar;&lt;br /&gt;
* [[jigar sirrozi]];&lt;br /&gt;
Boshqa turdagi kasalliklarda ikkilamchi tashxis maqsadida qoʻllanadi&amp;lt;ref&amp;gt;{{veb manbasi |title=D-димер |url=https://www.invitro.ru/moscow/library/labdiagnostika/27265/ |website=www.invitro.ru |publisher=Медицинская компания ИНВИТРО |accessdate=5-oktabr 2022-yil |date=13 Апреля 2022}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Qoʻllanilishi ==&lt;br /&gt;
D-dimerni quyidagi kasalliklarga tashxis qoʻyish maqsadida qoʻllanadi:&lt;br /&gt;
* trombotik holatlar (chuqur tomir trombozi, koʻpincha oʻpka emboliyasi bilan birga keladi);&lt;br /&gt;
* DVS-sindromi;&lt;br /&gt;
* homiladorlik davridagi asoratlar;&lt;br /&gt;
* COVID-19 va undan keyingi aʼsoratlar.&lt;br /&gt;
Bundan tashqari, tadqiqot antikoagulyant terapiyani kuzatish uchun ham zarur (uning davomiyligini, samaradorligini va buyurilgan dorilarning dozasini aniqlash maqsadida)&amp;lt;ref&amp;gt;{{kitob manbasi |last1=A.M. Jo&amp;#039;rayeva |title=Klinik laboratoriya |location=Andijon |edition=2019 |accessdate=5-oktabr 2022-yil}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Koʻrsatkichlari ==&lt;br /&gt;
D-dimer tahlili [[chuqur venoz tromboz]] (DVTl), [[o&amp;#039;pka emboliyasi]] (PE) yoki [[DVS sindromi|tarqalgan intravaskulyar koagulyatsiya]] (DIC) kasalliklariga shubha tugʻilganda klinik qoʻllanadi&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ponti&amp;quot;/&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
Chuqur venoz tromboz (DVTl) va oʻpka emboliyasii uchun ushbu kasalliklarning &amp;#039;&amp;#039;laboratoriya tahlili&amp;#039;&amp;#039; klinik ehtimolini aniqlash uchun ishlatiladigan turli xildagi tizimlari mavjud; ulardan eng mashhuri — [[Wells ball tahlili]]dir&amp;lt;ref&amp;gt;Ranasinghe A. M., Bonser R. S. Biomarkers in acute aortic dissection and other aortic syndromes. (angl.) // Journal of the American College of Cardiology. — 2010. — Vol. 56, no. 19. — P. 1535—1541. — doi:10.1016/j.jacc.2010.01.076. — PMID 21029872. [ispravit]&amp;lt;/ref&amp;gt;.&lt;br /&gt;
[[Fayl:Blut-EDTA.jpg|thumb|250px|right|D-dimerni aniqlash va laboratoriyaga yuborish uchun olingan qon naʼmunasi]]&lt;br /&gt;
&lt;br /&gt;
* Plazmadagi D-dimer darajasining oshishi bilan COVID-19 kasalligining ogʻirligining ortishi oʻrtasida sezilarli bogʻliqlik mavjud. Tizimli tekshiruv shuni koʻrsatadiki, 3,48 mkg/ml darajasi, bu ogʻir boʻlmagan/omon qolish holatlariga qaraganda besh baravar yuqori, kasalxonaga yotqizilgan COVID-19 bemorlarida yomon natijalarga olib kelishi mumkin&amp;lt;ref&amp;gt;{{Veb manbasi|muallif=Roy|ism=Molay|sana=2020-09-14|sarlavha=Elevated D-dimer is Associated with Severity of COVID-19 {{!}} Science Trend|url=https://sciencetrend.ca/2020/09/elevated-d-dimer-is-associated-with-severity-of-covid-19/|kirish sanasi=2021-08-15|til=en-US|arxivsana=2021-08-15|arxivurl=https://web.archive.org/web/20210815213731/https://sciencetrend.ca/2020/09/elevated-d-dimer-is-associated-with-severity-of-covid-19/}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* Yuqori ball yoki testdan oldingi ehtimollik uchun D-dimer kam farq qiladi va test natijalaridan qatʼi nazar, [[Antikoagulyantlar|antikoagulyant]] terapiya boshlanadi va DVT yoki oʻpka emboliyasi uchun qoʻshimcha tekshiruv oʻtkazilishi mumkin.&lt;br /&gt;
* Oʻrtacha yoki past ball yoki testdan oldingi ehtimollik uchun:&lt;br /&gt;
** Salbiy D-dimer testi tromboemboliyani deyarli istisno qiladi&amp;lt;ref&amp;gt; Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, et al. (September 2003). „Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis“. The New England Journal of Medicine. 349 (13): 1227-35. doi:10.1056/NEJMoa023153. PMID 14507948.&amp;lt;/ref&amp;gt;. D-dimerning trombolitik kasallik ehtimolini kamaytirish darajasi klinik sharoitda qoʻllanadigan maxsus testning sinov xususiyatlariga bogʻliq: eng mavjud boʻlgan holatlarda D-dimer salbiy natijaga ega boʻlgan testlar, agar testdan oldingi ehtimollik 15-20 % dan kam boʻlsa, tromboembolik kasallik ehtimolini 1 % dan kamroq kamaytiradi. Koʻkrak qafasining [[kompyuter tomografiyasi]] (KT angiografiyasi) D-dimer tahlilining salbiy natijalari boʻlgan odamlarda oʻpka emboliyasini baholash uchun ishlatilmasligi kerak&amp;lt;ref name=&amp;quot;ACCPandATSfive&amp;quot;&amp;gt;{{Citation|last=American College of Chest Physicians|author1-link=American College of Chest Physicians|last2=American Thoracic Society|author2-link=American Thoracic Society|date=September 2013|title=Five Things Physicians and Patients Should Question|publisher=American College of Chest Physicians and American Thoracic Society|journal=[[Choosing Wisely]]: an initiative of the [[ABIM Foundation]]|url=http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/|access-date=6 January 2013|archivedate=2013-11-03|archiveurl=https://web.archive.org/web/20131103063427/http://www.choosingwisely.org/doctor-patient-lists/american-college-of-chest-physicians-and-american-thoracic-society/}}.&amp;lt;/ref&amp;gt;. Testdan oldingi past ehtimollik ham oʻpka emboliyasini istisno qilishda muhim ahamiyatga ega&amp;lt;ref&amp;gt;{{jurnal manbasi|title=D-dimer test for excluding the diagnosis of pulmonary embolism|journal=The Cochrane Database of Systematic Reviews|issue=8|pages=CD010864|date=August 2016|pmid=27494075|pmc=6457638|doi=10.1002/14651858.CD010864.pub2|editor-last=Cochrane Vascular Group}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
** Agar D-dimer yuqori boʻlsa, tromb borligini tasdiqlash uchun qoʻshimcha tekshiruvlar (oyoq tomirlarining [[Ultratovush tekshirish usuli|ultratovush tekshiruvi]] yoki oʻpka sintigrafiyasi yoki KT skanerlashi) talab qilinadi. [[Antikoagulyantlar|Antikoagulyant]] terapiya shu nuqtada boshlanishi mumkin yoki klinik vaziyatga qarab keyingi testlar tashxisni tasdiqlamaguncha toʻxtatilishi mumkin.&lt;br /&gt;
&lt;br /&gt;
Baʼzi shifoxonalarda kasallikka shubxa tugʻilganda tekshiruv natijalaridan soʻng va faqat tahminiy tahlil natijasi koʻrsatilgan normadan past yoki oʻrta boʻlsa, ular laboratoriyalar tomonidan oʻlchanadi. Bu ehtimolligi yuqori boʻlgan bemorlarda keraksiz natijalarga boʻlgan ehtiyojni kamaytiradi&amp;lt;ref&amp;gt;{{jurnal manbasi|title=Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings|url=https://archive.org/details/sim_chest_2004-03_125_3/page/851|journal=Chest|volume=125|issue=3|pages=851–5|date=March 2004|pmid=15006941|pmc=1215466|doi=10.1378/chest.125.3.851}}&amp;lt;/ref&amp;gt;. Avval D-dimer tahlilini oʻtkazib koʻrish tahminiy tashxis qoʻyishning muhim qismini oldini oladi va kamroq invaziv hisoblanadi. D-dimer diagnostikaga boʻlgan ehtiyojni istisno qilishi mumkinligi sababli, maxsus professional tashkilotlar shifokorlarga D-dimer testini dastlabki tashxis sifatida qoʻllashni tavsiya qiladi&amp;lt;ref name=&amp;quot;ACPfive&amp;quot;&amp;gt;{{Citation|last=American College of Physicians|author1-link=Consumer Reports|others=presented by [[ABIM Foundation]]|title=Five Things Physicians and Patients Should Question|publisher=[[American College of Physicians]]|journal=Choosing Wisely|url=http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_Amer_College_Phys.pdf|access-date=August 14, 2012|archiveurl=https://web.archive.org/web/20120624075449/http://choosingwisely.org/wp-content/uploads/2012/04/5things_12_factsheet_Amer_College_Phys.pdf|archivedate=June 24, 2012}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ACEPembolism&amp;quot;&amp;gt;{{jurnal manbasi|title=Critical issues in the evaluation and management of adult patients presenting to the emergency department with suspected pulmonary embolism|journal=Annals of Emergency Medicine|volume=57|issue=6|pages=628–652.e75|date=June 2011|pmid=21621092|doi=10.1016/j.annemergmed.2011.01.020|last8=American College of Emergency Physicians}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;ECSpulemb&amp;quot;&amp;gt;{{jurnal manbasi|display-authors=6|title=Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC)|journal=European Heart Journal|volume=29|issue=18|pages=2276–315|date=September 2008|pmid=18757870|doi=10.1093/eurheartj/ehn310}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;AAFPthrombo&amp;quot;&amp;gt;{{jurnal manbasi|display-authors=6|title=Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians|journal=Annals of Family Medicine|volume=5|issue=1|pages=57–62|year=2007|pmid=17261865|pmc=1783928|doi=10.1370/afm.667}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Izoh ==&lt;br /&gt;
&lt;br /&gt;
=== Maʼlumot diapazonlari ===&lt;br /&gt;
Quyida D-dimer uchun hos boʻlgan maʼlumotlar diapazonlari keltirilgan&amp;lt;ref&amp;gt;[http://www.perinatology.com/Reference/Reference%20Ranges/D-Dimer.htm Reference Values During Pregnancy] at perinatology.com. Retrieved October 2014.&amp;lt;/ref&amp;gt;.&lt;br /&gt;
{| class=&amp;quot;wikitable&amp;quot;&lt;br /&gt;
!Birliklar&lt;br /&gt;
! Homilador boʻlmagan&amp;lt;br /&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;br /&amp;gt;&amp;lt;nowiki&amp;gt;&amp;lt;/br&amp;gt;&amp;lt;/nowiki&amp;gt; kattalar&lt;br /&gt;
! Birinchi [[Homiladorlik|trimestr]]&lt;br /&gt;
! Ikkinchi trimestr&lt;br /&gt;
! Uchinchi trimestr&lt;br /&gt;
|-&lt;br /&gt;
| mg/l yoki mkg/ml&lt;br /&gt;
| &amp;lt; 0,5&lt;br /&gt;
| 0,05 - 0,95&lt;br /&gt;
| 0,32 - 1,29&lt;br /&gt;
| 0,13 -1,7&lt;br /&gt;
|-&lt;br /&gt;
| mkg/L yoki ng/ml&lt;br /&gt;
| &amp;lt; 500&lt;br /&gt;
| 50 - 950&lt;br /&gt;
| 320 - 1290&lt;br /&gt;
| 130 - 1700&lt;br /&gt;
|-&lt;br /&gt;
| nmol/l&lt;br /&gt;
| &amp;lt; 2.7&lt;br /&gt;
| 0,3 - 5,2&lt;br /&gt;
| 1,8 - 7,1&lt;br /&gt;
| 0,7 - 9,3&lt;br /&gt;
|}&lt;br /&gt;
D-dimer inson yoshi kattalashgan sari ortib boradi. Shuning uchun [[venoz tromboemboliya]] (VTE) shubha boʻlganda 50 yoshdan oshgan bemorlar uchun bemorning yoshiga teng boʻlgan yil × 10 mkg/L (yoki x 0,056 nmol/L) chegarani qoʻllash taklif qilingan, chunki bu notoʻgʻri natijani kamaytiradi, notoʻgʻri salbiy davolash choralarini sezilarli darajada amalga oshirmaslikka kafolat boʻladi&amp;lt;ref&amp;gt;{{jurnal manbasi|title=PURLs: It&amp;#039;s time to use an age-based approach to D-dimer|journal=The Journal of Family Practice|volume=63|issue=3|pages=155–8|date=March 2014|pmid=24701602|pmc=4042909}}&amp;lt;/ref&amp;gt;&amp;lt;ref&amp;gt;{{jurnal manbasi|title=Evaluation of Patients With Suspected Acute Pulmonary Embolism: Best Practice Advice From the Clinical Guidelines Committee of the American College of Physicians|journal=Annals of Internal Medicine|volume=163|issue=9|pages=701–11|date=November 2015|pmid=26414967|doi=10.7326/M14-1772}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
D-dimerning muqobil oʻlchovi fibrinogen ekvivalent birliklarida (FEU) keltiriladi. Fibrinogen molekulasining molekulyar ogʻirligi D-dimer molekulasining oʻlchamidan taxminan ikki baravar katta va shuning uchun 1,0 mkg/ml FEU 0,5 mkg/ml d-dimerga teng&amp;lt;ref&amp;gt;{{Veb manbasi|url=http://education.questdiagnostics.com/faq/FAQ149|sarlavha=Clinical Education Center|ish=Quest Diagnostics}} Document FAQS.149 Version: 3 effective 07/23/2019 to present&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
=== Tromboz kasalligi ===&lt;br /&gt;
D-dimer qondagi boʻlgan oʻzgarishlarining deyarli 93-95 % gacha sezgirlikka ega (haqiqiy ijobiy koʻrsatkich). Shifoxonaga yotqizilgan har bir bemorlar uchun trombolitik kasalligi tashxisi uchun amalga oshirilgan oʻziga xos tekshiruv usullarining taxminan 50 % aniq tashxis qoʻyish uchun aniqlik (notoʻgʻri ijobiy koʻrsatkich bilan bogʻliq) ekanligini aniqladi.&amp;lt;ref&amp;gt;{{jurnal manbasi|title=Comparison of diagnostic accuracies in outpatients and hospitalized patients of D-dimer testing for the evaluation of suspected pulmonary embolism|url=https://archive.org/details/sim_clinical-chemistry_2003-09_49_9/page/1483|journal=Clinical Chemistry|volume=49|issue=9|pages=1483–90|date=September 2003|pmid=12928229|doi=10.1373/49.9.1483}}&amp;lt;/ref&amp;gt;&lt;br /&gt;
&lt;br /&gt;
* Notoʻgʻri ijobiy koʻrsatkichlar turli sabablarga koʻra boʻlishi mumkin: [[jigar]] kasalligi, yuqori revmatoid omil, [[Yalligʻlanish|yalligʻlanish]], [[Saraton (kasallik)|malignite]], [[travma]], [[homiladorlik]], yaqinda oʻtkazilgan [[Xirurgiya|jarrohlik]] amaliyoti, shuningdek, keksa yosh&amp;lt;ref&amp;gt;{{jurnal manbasi|display-authors=6|title=Factors associated with positive D-dimer results in patients evaluated for pulmonary embolism|journal=Academic Emergency Medicine|volume=17|issue=6|pages=589–97|date=June 2010|pmid=20624138|pmc=3538031|doi=10.1111/j.1553-2712.2010.00765.x}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* Agar namuna tromb hosil boʻlganidan keyin juda erta olingan boʻlsa yoki sinov bir necha kunga kechiktirilsa, notoʻgʻri salbiy koʻrsatkichlar paydo boʻlishi mumkin. Bundan tashqari, antikoagulyantning mavjudligi testni salbiy koʻrsatishi mumkin, chunki u trombning kengayishini oldini oladi. Antikoagulyatsion dorilar dabigatran va rivaroksaban D-dimer darajasini pasaytiradi, ammo D-dimer tahliliga xalaqit bermaydi&amp;lt;ref name=&amp;quot;BaglinKeeling2012&amp;quot;&amp;gt;{{jurnal manbasi|title=Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology|journal=British Journal of Haematology|volume=159|issue=4|pages=427–9|date=November 2012|pmid=22970737|doi=10.1111/bjh.12052}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
* Namuna yigʻish trubkasi etarli darajada toʻldirilmagan boʻlsa, notoʻgʻri qiymatlar olinishi mumkin (agar kam toʻldirilgan boʻlsa, notoʻgʻri past qiymat va ortiqcha toʻldirilgan boʻlsa, notoʻgʻri yuqori qiymat). Bu antikoagulyantning suyultiruvchi taʼsiriga bogʻliq (qonni antikoagulyantga nisbati 9:1 nisbatda toʻplash kerak).&lt;br /&gt;
* Test tahlilidan oldingi natijani sozlash uchun ehtimollik nisbatlari sezgirlik va oʻziga xoslikdan kelib chiqadi.&lt;br /&gt;
&lt;br /&gt;
D-dimer tahlilini talqin qilishda, 50 yoshdan oshgan bemorlar uchun (bemorning yoshi) × 10 mkg/L qiymati anormal boʻlish ehtimoli mavjud&amp;lt;ref name=&amp;quot;pmid22072293&amp;quot;&amp;gt;{{jurnal manbasi|display-authors=6|title=The combination of four different clinical decision rules and an age-adjusted D-dimer cut-off increases the number of patients in whom acute pulmonary embolism can safely be excluded|journal=Thrombosis and Haemostasis|volume=107|issue=1|pages=167–71|date=January 2012|pmid=22072293|doi=10.1160/TH11-08-0587}}&amp;lt;/ref&amp;gt;&amp;lt;ref name=&amp;quot;pmid20354012&amp;quot;&amp;gt;{{jurnal manbasi|display-authors=6|title=Potential of an age adjusted D-dimer cut-off value to improve the exclusion of pulmonary embolism in older patients: a retrospective analysis of three large cohorts|journal=BMJ|volume=340|pages=c1475|date=March 2010|pmid=20354012|pmc=2847688|doi=10.1136/bmj.c1475}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Tarixi ==&lt;br /&gt;
D-dimer dastlab 1970-yillarda tasvirlangan va 1990-yillarda ilmiy izlanishlar natijasida uning diagnostik qoʻllanishiga oid maʼlumotlar topilgan&amp;lt;ref&amp;gt;{{jurnal manbasi|last=Asakura|first1=Hidesaku|last2=Ogawa|first2=Haruhiko|title=COVID-19-associated coagulopathy and disseminated intravascular coagulation|journal=International Journal of Hematology|volume=113|issue=1|year=2020|issn=0925-5710|pmid=33161508|pmc=7648664|doi=10.1007/s12185-020-03029-y|pages=45–57}}&amp;lt;/ref&amp;gt;.&lt;br /&gt;
&lt;br /&gt;
== Yana qarang ==&lt;br /&gt;
* [https://www.youtube.com/watch?v=i_tuLj1b0Yk Koagulogramma koʻrsatkichlari]&lt;br /&gt;
* [https://www.youtube.com/watch?v=gPVOlFIllZk Trombotsitlar Faolyati. Jarohat Bitishi mexanizmi]&lt;br /&gt;
&lt;br /&gt;
== Manbalar ==&lt;br /&gt;
{{manbalar}}&lt;br /&gt;
&lt;br /&gt;
== Havolalar ==&lt;br /&gt;
* [http://labtestsonline.org/understanding/analytes/d-dimer/tab/test D-dimer] {{Webarxiv|url=https://web.archive.org/web/20170728005846/http://labtestsonline.org/understanding/analytes/d-dimer/tab/test |date=2017-07-28 }} — Onlayn laboratoriya testlari&lt;br /&gt;
&lt;br /&gt;
== Adabiyotlar ==&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;M. A. Jurayeva&amp;#039;&amp;#039;&amp;#039; &amp;#039;&amp;#039;&amp;quot;Klinik laborator tahlillarini interpretatsiya qilish&amp;quot;&amp;#039;&amp;#039; A — 2019&lt;br /&gt;
&lt;br /&gt;
[[Turkum:Gematologiya]]&lt;br /&gt;
[[Turkum:Angiologiya]]&lt;br /&gt;
[[Turkum:Koagulogramma]]&lt;br /&gt;
[[Turkum:COVID-19]]&lt;br /&gt;
[[Turkum:Virusologiya]]&lt;br /&gt;
[[Turkum:Yuqumli kasalliklar]]&lt;br /&gt;
[[Turkum:Laboratoriya diagnostikasi]]&lt;br /&gt;
[[Turkum:1970-yilgi kashfiyotlar]]&lt;br /&gt;
[[Turkum:1990-yilgi kashfiyotlar]]&lt;/div&gt;</summary>
		<author><name>Programmer</name></author>
	</entry>
</feed>